Cardiac failure
Not yet recruitingEffect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery
Effect of Continuing vs Stopping Dapagliflozin (with other drug combinations) on 30‑Day Cardiovascular Outcomes in Heart Failure Patients Undergoing Cardiac Surgery
- Disease:Cardiac failure
- Substances:DapagliflozinEmpagliflozin+1
France- Participants:18–64 years · 65+ years
- Substances:Dapagliflozin
- Sponsor:Centre Hospitalier Universitaire De Toulouse







